BEIJING-ZHENWEI
30.3.2016 09:02:01 CEST | Business Wire | Press release
The 5th Beijing International Import Food Expo 2016 (cipfe 2016) will take place on 6th -8th May, 2016 at Beijing Exhibition Center. With an exhibition area of 20,000m2 , cipfe 2016 will present 10 pavilions covering leisure food (chocolates, candies, nuts and etc), coffee and tea, beverage, organic food, wines and beers, dairy, oil, meat, etc. Over 600 international food enterprises from more than 30 countries and regions are expected to attend the exhibition, including US, Italy, Spain, Australia, Thailand, South Korea and Malaysia.
Under the theme of “Share the Global Taste”, the organizers of the event, China Chamber of International Commerce (CCOIC) and Zhenwei Exhibition Group, will provide the biggest national-level imported food trade platform for over 32,000 visitors, including import-export traders, food distributors, supermarkets, hotels, restaurants, top clubs and other related industry sectors. As one of the highlights in the exhibition, numerous buyers will also seek potential consumers and enlarge their business cooperation in Asian market.
In order to attract the most influential targeted visitors during the three-day event, the diamond buyers invitation group of cipfe 2016 will identify valuable buyers and establish and maintain contact with them, so that the exhibitors can learn the latest ideas and thoughts of the attendees. Meanwhile, some seminars such as Products Promotion Seminar, Oversea Products Purchasing Seminar and World Delicacy Tasting Seminar will be concurrently held during the exhibition.
Besides, over 100 mainstream media like People’s Daily, CCTV, Xinhua, China Daily, Beijing TV Station, sina.com.cn, ifeng.com, sohu.com, China Taiwan and Asia Food will attend the event and offer the latest industry information and investment opportunities for visitors and buyers worldwide. Furthermore, Business Recruitment Agency Conference, World Food Tasting Conference and Networking of Shop, Supermarket and E-commerce will also create great chances for both traders and buyers to learn the development trend of the food industry and make long-term win-win collaborations.
More information about cipfe 2016, please visit: www.cipfe.com .
About cipfe
Beijing International Import Food Expo (cipfe) is the only one National-level import food expo in Beijing. The CCOIC and Zhenwei will build a famous Brand Exhibition Project, and make full use of the 200,000 professional database, which include the international buyers in China, Food agencies, Supermarket, High-end club etc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160330005027/en/
Contact:
Beijing Zhenwei Exhibition Co., Ltd.
Margaret Duan or Cassidy Liu,
+8613910314389, +86-10-58236512
cipfe@zhenweiexpo.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom